The importance of cardiovascular health in relation to pregnancy outcome is increasingly acknowledged. Women who develop certain pregnancy complications, in particular preeclampsia, are at higher risk for future cardiovascular disease. Independent of its outcome, pregnancy requires a substantial adaptive response of the maternal cardiovascular system. In the HAPPO study, we aim to examine longitudinal maternal hemodynamic adaptation to pregnancy from the preconception period onwards. We hypothesize that women who will develop adverse pregnancy outcomes have impaired cardiovascular health before conception, leading to hemodynamic maladaptation to pregnancy and diminished uteroplacental vascular development.
 Hemodynamic adaptation to pregnancy will be measured prospectively from the preconception period onwards to three months post-delivery, thereby covering an important window in the reproductive timespan.
 Simultaneous assessment of maternal hemodynamic adaptation to pregnancy and uteroplacental vascular development will provide new insights into the interaction between both mechanisms and the pathophysiology of pregnancy complications.
 Since only multiparous women will be included, conclusions about whether maternal hemodynamic maladaptation is a cause or consequence of previous pregnancy outcome cannot be provided. Placenta-related pregnancy complications (PPC), such as preeclampsia and/or foetal growth restriction, occur in approximately 10-15% of all pregnancies. [1] [2] [3] PPC not only affect perinatal morbidity and mortality but also significantly impact the long-term cardiovascular health of women and their children with associated health care costs for society. [4] [5] [6] For example, women with a history of preeclampsia have a two-to sevenfold increased risk to develop ischemic heart disease in later life, depending on the gestational age and severity at onset of preeclampsia. 4 Thus, early identification of women who are at risk for PPC is not only important to enable subsequent personalized prevention and treatment strategies in order to improve reproductive outcome, but also to improve lifelong cardiovascular health. To date, most available screening tests for adverse pregnancy outcome use blood pressure and uterine artery blood flow, which reflect the hemodynamic profile of the mother, and thereby the likelihood of impaired placental development and subsequent adverse events. Nonetheless, these markers are not directly related to cardiac or placental function, which may explain the moderate predictive performances of most prognostic models. 7 8 Hemodynamic adaptation to pregnancy Pregnancy requires a physiological adaptive response of the maternal cardiovascular system with a substantial rise in plasma volume and cardiac output (CO). 9 Already in the first trimester of pregnancy, a woman's systemic vascular resistance decreases with 35-40% and her stroke volume increases with 8%. 9 This natural volume overload leads to a reversible, physiological left ventricular dilatation and a possible change in left ventricular diastolic function. 10 In most pregnancies, these changes occur without clinical problems. However, in women who develop PPC, maternal hemodynamic adaptation can be different and diastolic dysfunction is more often present. 11 12 Moreover, in women with complicated pregnancies, endothelial dysfunction and increased vascular stiffness are also more common. 13 14 The endothelial lining of the vasculature in the human body is of great importance in the regulation of vascular tone. Vascular stiffness increases during normal aging by the replacement of elastin fibres with less elastic collagen.
Endothelial function tests and arterial vascular stiffness measurements have already proven to be of importance in predicting cardiovascular disease. 15 Page 5 of 21
For peer review only -http://bmjopen.bmj.com/site/about/guidelines.xhtml BMJ Open   1  2  3  4  5  6  7  8  9  10  11  12  13  14  15  16  17  18  19  20  21  22  23  24  25  26  27  28  29  30  31  32  33  34  35  36  37  38  39  40  41  42  43  44  45  46  47  48  49  50  51  52  53  54  55  56  57  58  59 Together, this all supports the hypothesis that in women who develop PPC an increased risk for cardiovascular disease is unmasked by the stressed state of pregnancy. 16 17 However, knowledge on maternal hemodynamic adaptation to pregnancy, as early as the time of conception, is scarce and often only focuses on one or two parameters instead of the complex interaction between macro-and microcirculatory parameters. Only a few studies starting prior to pregnancy have shown hemodynamic changes in, for example, blood pressure, heart rate and CO early in pregnancy. [18] [19] [20] [21] [22] An integrated approach using parallel techniques and multiple hemodynamic parameters from the preconception period onwards throughout pregnancy is needed to provide insight in individual (patho)physiological hemodynamic adaptation to pregnancy.
Placental development and function
The adequate establishment of the maternal-foetal vascular interface early in gestation is essential for a healthy pregnancy outcome. Among others, this requires adaptation of the uterine spiral arteries into remodelled vessels to create a low-resistance uteroplacental circulation. 23 24 Failure in the adaptation of the uterine vasculature causes hypoperfusion of the placenta and is widely believed to underlie several pregnancy complications. 25 26 This is substantiated by several changes in histopathology, including decidual vasculopathy, villous hypoplasia and lesions consistent with loss of integrity of the vascular wall of the maternal circulation in delivered placentas of women with PPC. [27] [28] [29] However, the aetiology of these placental abnormalities and its relation with maternal cardiovascular health remains unclear.
RESEARCH HYPOTHESIS AND AIM
We hypothesize that impaired maternal cardiovascular health leads to hemodynamic maladaptation to pregnancy, diminished uteroplacental vascular development and subsequent pregnancy complications (Figure 1 ). The overall aim of the HAPPO study is to examine associations between maternal hemodynamic adaptation to pregnancy and (utero)placental vascular development in women with and without pregnancy complications.
Therefore, we specified the following objectives:
1. To assess hemodynamic parameters before, during and after pregnancy to gain insight in (patho)physiological maternal hemodynamic adaptation mechanisms; 1  2  3  4  5  6  7  8  9  10  11  12  13  14  15  16  17  18  19  20  21  22  23  24  25  26  27  28  29  30  31  32  33  34  35  36  37  38  39  40  41  42  43  44  45  46  47  48  49  50  51  52  53  54  55  56  57  58  59 4. To study differences in baseline hemodynamic parameters and hemodynamic adaptation to pregnancy between women with and without a history of PPC .
STUDY DESIGN
The HAPPO study is a single-centre prospective cohort study, embedded in the ongoing percentile, absent or reversed end-diastolic flow in the umbilical artery or a cerebroplacental ratio <1. 33 Also, 100 women after uncomplicated pregnancies and (term) deliveries will be included as a low-risk control group. Women are eligible to participate in this study when they have a minimum age of 18 years, the delivery date of their last pregnancy was more than one year ago, they have a current wish to become pregnant and the previous pregnancy was either complicated by PPC or the previous pregnancy was uncomplicated. Women who are unable or unwilling to provide informed consent will be excluded from participation. Also, if a woman 1  2  3  4  5  6  7  8  9  10  11  12  13  14  15  16  17  18  19  20  21  22  23  24  25  26  27  28  29  30  31  32  33  34  35  36  37  38  39  40  41  42  43  44  45  46  47  48  49  50  51  52  53  54  55  56  57  58  59  60   F  o  r  p  e  e  r  r  e  v  i  e  w  o  n  l  y is currently breastfeeding, she will be excluded from participation since this may influence her vascular condition. The in-and exclusion criteria are shown in Table 1 . Table 1 . Inclusion and exclusion criteria for participants in the HAPPO study.
STUDY PROCEDURES/MEASUREMENTS
An overview of all study procedures is provided in Figure 2 . The first study visit will be planned when the participating woman has the wish to become pregnant, but before conception takes place. When a pregnancy occurs within one year, a study visit will be planned in each trimester as well as three months post-delivery, which will be the last study visit.
Questionnaires
Participants of the study will receive a total of three questionnaires: 1) after the preconceptional study visit, participants will receive an online questionnaire on demographic characteristics, medical conditions and lifestyle; 2) preceding the study visit in the first trimester of pregnancy, participants will receive an online questionnaire to address possible changes in medical conditions and lifestyle; 3) after delivery, participants will receive an online follow-up questionnaire on pregnancy and birth outcomes (i.e. gestational age at birth, mode of delivery, birth weight, neonatal sex, pregnancy and/or delivery complications).
Anthropometrics
At each visit, a woman's height, weight, hip and waist circumference will be measured using 1  2  3  4  5  6  7  8  9  10  11  12  13  14  15  16  17  18  19  20  21  22  23  24  25  26  27  28  29  30  31  32  33  34  35  36  37  38  39  40  41  42  43  44  45  46  47  48  49  50  51  52  53  54  55  56  57  58  59  60   F  o  r  p  e  e  r  r  e  v  i  e  w  o  n  l  y Two blood samples (8.5mL serum tube and 10mL EDTA tube) will be obtained at the preconception visit, the first-and third-trimester visit, and the post-delivery visit. All samples will be centrifuged and divided into aliquots of serum, plasma, whole blood and buffy coat and then stored in a -80°C freezer at the trial laboratory at our own facility for future assessment of cardiovascular markers (e.g. CRP and lipids) and markers of placental function (e.g. PlGF and sFlt-1).
Echocardiography
Transthoracic echocardiography has become the preferential method for safe, non-invasive cardiac assessment in pregnant women. 35 36 At all study visits, echocardiography will be performed using an Affiniti 70G ultrasound machine (Philips Healthcare, Andover, United 
Post occlusion reactive hyperaemia
One of the first manifestations of an impaired cardiovascular risk profile is endothelial dysfunction of small vessels (microcirculation). Post occlusion reactive hyperaemia (PORH) will be used in this study to assess the endothelial function of the peripheral microvasculature.
We use devices from Moor instruments (moorVMS-VASC 2.0, moorVMS-PRES and moorVMS-LDF; Axminster, United Kingdom) to measure microvascular blood flow reactivity following arterial occlusion by using a non-invasive laser Doppler flowmetry (LDF) technique. In resting position, after three minutes of arterial occlusion by a cuff surrounding the upper left arm, the reperfusion of microvascular blood in the skin is measured by the LDF skin probe which is attached to the lower arm. The peak response after the release of the occlusion and the time to recover to baseline reflect endothelial regulated microvascular function. 39 40 41 42 Pulse wave velocity values are derived from an algorithm which integrates age, central systolic blood pressure and data derived from pulse wave analysis into a mathematical model. 43 Higher values of pulse wave velocity indicate higher arterial stiffness and thus a worse vascular condition. The AIx provides additional information on the stiffness of the aorta and is derived from the central pressure waveform.
Cardiopulmonary exercise test with bio-impedance cardiography
To assess the hemodynamic response during physical stress, CO will also be measured using signal morphology impedance cardiography (SM-ICG) using PhysioFlow® PF07 Enduro (Manatec biomedical, Poissy, France). The exercise during which the SM-ICG will be performed, is a cardiopulmonary exercise test (CPET) on a cycle ergometer with a RAMP protocol to 70% of the estimated maximum heart rate according to the Tanaka formula. 44 Moderate exercise limited to 70% of the maximal heart rate is considered safe during pregnancy. 45
Uteroplacental vascularization measurements
Studies using conventional two-dimensional (2D) Doppler ultrasound have shown that increased vascular resistance of the uterine arteries is associated with an increased risk for subsequent development of PPC. 7 46 Therefore, pulsed wave Doppler measurements of the right and left uterine artery will be performed at all study visits to provide the pulsatility and resistance indices. Moreover, to evaluate the morphology of the uterine and placental vasculature and quantification of perfusion, a 3D power Doppler scan of the uterine (preconception visit) and placental bed (first-trimester visit) vasculature will be performed, also using the Affiniti 70G ultrasound machine. By assessing these 3D datasets in an innovative virtual reality ( Obstetrics and Gynaecology (ISUOG) are followed for the purpose of this study (i.e. thermal index (TI) ≤ 1.0, mechanical index (MI) <1.9 and total exposure time < 10 min). Transvaginal scanning time (preconception and first trimester) and transabdominal scanning time (second and third trimester) will be kept as short as possible according to the ALARA principles. 49 50 
Embryonic and foetal growth parameters
At the first trimester visit, additional parameters of embryonic growth will be measured, i.e. crown-rump length and embryonic volume. The obtained 3D datasets will be visualized in the Barco I-Space or desktop version and offline volume measurements will be performed.
At the second and third trimester visit, additional parameters of foetal growth (head circumference, abdominal circumference, femur length) and pulsed wave Doppler measurements of the umbilical artery and median cerebral artery will be performed by transabdominal ultrasound.
Placental examinations
At delivery, histological samples of in vivo placental vasculature will be harvested. The placenta will be collected according to standard procedures and four samples of approximately 3cm*3cm are then fixated in 4% paraformaldehyde for storage. The fixated placenta biopsies will be processed and studied as done in routine placental pathology examination.
In a subgroup of women who undergo a caesarean section (estimated 30% of our study population) at the Erasmus MC, four punch biopsies of the placental bed will be collected, which consist of decidual and myometrial tissue and contain spiral arteries. 51 The samples are directly rinsed with sterile NaCl to wash excessive blood and then fixated in 4% paraformaldehyde for storage and examination. According to our previously published protocol, several markers will be used to score the developmental state of the spiral arteries, identifying typical acute atherosis lesions and evaluating involvement of the immune system. 51 52 1  2  3  4  5  6  7  8  9  10  11  12  13  14  15  16  17  18  19  20  21  22  23  24  25  26  27  28  29  30  31  32  33  34  35  36  37  38  39  40  41  42  43  44  45  46  47  48  49  50  51  52  53  54  55  56  57  58  59 The primary outcome measure of the HAPPO study is the difference in maternal hemodynamic adaptation to pregnancy, expressed as the trajectory of CO assessed by echocardiography before, during and after pregnancy, between women who do and do not develop PPC. CO is one of the most frequently described hemodynamic parameters in pregnancy, alongside with blood pressure. By using transthoracic echocardiography, as a validated and safe method to measure CO, we will obtain consecutive and reliable information on maternal hemodynamic adaptation to pregnancy. 36 The secondary outcome measures are differences in additional indices of maternal 
OUTCOME MEASURES

SAMPLE SIZE CALCULATION
Since we aim to investigate multiple hemodynamic parameters and literature on this subject is scarce, sample sizes are difficult to calculate. There are a few studies that describe the longitudinal trajectory of CO from preconception until after delivery in uncomplicated pregnancies and a couple of cross-sectional studies that investigated CO in either the first of third trimester of pregnancy. 18-20 54 55 Based on these studies, we expect a difference of approximately 0.5 standard deviation (SD) at each time point and an intraclass correlation coefficient of at least 0.3 between time points in our study. With alpha set at 0.05 and a power of 0.8, simulation for linear mixed model analysis based on these estimates showed that 38 cases (PPC in the anticipated pregnancy) are needed to establish such differences. 56 Based on literature, we expect a 25% recurrence rate of PPC in the high-risk group and a 2% incidence of PPC in the low-risk group. 57-59 Thus, PPC cases will primarily occur in the high-risk
group. For an expected number of 38 cases we would need to follow-up 38/0.25=152 pregnancies in the high-risk group.
Multiparous women who wish to become pregnant who are actively contemplating pregnancy, are assumed to have an approximately 85% chance to become pregnant again within one year. 60 61 The overall miscarriage rate in this study group is estimated to be 1  2  3  4  5  6  7  8  9  10  11  12  13  14  15  16  17  18  19  20  21  22  23  24  25  26  27  28  29  30  31  32  33  34  35  36  37  38  39  40  41  42  43  44  45  46  47  48  49  50  51  52  53  54  55  56  57  58  59 
STATISTICAL ANALYSIS PLAN
Patient characteristics, medical conditions and lifestyle data will be presented as means [SD] or numbers [percentage] and compared using t-tests and chi-square tests. Hemodynamic parameters will be presented as means [SD] at each time point and compared between groups using t-tests.
Multivariate linear mixed models will be used to analyse the trajectories of maternal hemodynamic parameters over time. We will test whether there is a difference between women who do and do not develop PPC by comparing each trajectory using a likelihood ratio test.
Subgroup analyses will be performed to study (baseline and trajectory) differences between high-and low-risk women, independent of subsequent pregnancy outcome. Bonferroni corrections will be applied to control for multiplicity of secondary outcome parameters.
In case of significant differences in patient characteristics between groups, regression analyses will be adjusted for these characteristics.
DATA COLLECTION, HANDLING AND STORAGE
The study will be performed according to written informed consent procedures which ensures personal data protection and confidentiality. Data will be de-identified (pseudo-anonymized) in order to guarantee the privacy of the participants, the key to the code will be safeguarded by the investigators and will remain on site with the local research team.
All research data will be retained and stored in the HAPPO-database at a secured server at the research institution and it will remain there for at least 15 years after completion of the 1  2  3  4  5  6  7  8  9  10  11  12  13  14  15  16  17  18  19  20  21  22  23  24  25  26  27  28  29  30  31  32  33  34  35  36  37  38  39  40  41  42  43  44  45  46  47  48  49  50  51  52  53  54  55  56  57  58  59 
ETHICS AND DISSEMINATION
The study will be conducted according to the principles of the Declaration of Helsinki (version The HAPPO study team invites colleagues who are interested in collaboration or data sharing to contact the principal investigators at HAPPO.studie@erasmusmc.nl.
Results of the study will be disseminated to healthcare professionals and to scientific and industrial peers through events, professional organizations and publications in peer-reviewed (preferably open-access) journals as well as presentations at scientific congresses. Also, results will be communicated to women who wish to become pregnant and women who experienced pregnancy complications by informing patient associations and by dissemination via (social) media.
FUTURE IMPLICATIONS
The results of this study will provide more understanding of longitudinal maternal hemodynamic adaptation to pregnancy in relation to utero(placental) vascular development and its associations with subsequent pregnancy outcome. Hereby, starting points for future possibilities to optimize cardiovascular and placental health by interventions in clinical 1  2  3  4  5  6  7  8  9  10  11  12  13  14  15  16  17  18  19  20  21  22  23  24  25  26  27  28  29  30  31  32  33  34  35  36  37  38  39  40  41  42  43  44  45  46  47  48  49  50  51  52  53 
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None declared. 1  2  3  4  5  6  7  8  9  10  11  12  13  14  15  16  17  18  19  20  21  22  23  24  25  26  27  28  29  30  31  32  33  34  35  36  37  38  39  40  41  42  43  44  45  46  47  48  49  50  51  52  53 1  2  3  4  5  6  7  8  9  10  11  12  13  14  15  16  17  18  19  20  21  22  23  24  25  26  27  28  29  30  31  32  33  34  35  36  37  38  39  40  41  42  43  44  45  46  47  48  49  50  51  52  53 1  2  3  4  5  6  7  8  9  10  11  12  13  14  15  16  17  18  19  20  21  22  23  24  25  26  27  28  29  30  31  32  33  34  35  36  37  38  39  40  41  42  43  44  45  46  47  48  49  50  51  52  53 1  2  3  4  5  6  7  8  9  10  11  12  13  14  15  16  17  18  19  20  21  22  23  24  25  26  27  28  29  30  31  32  33  34  35  36  37  38  39  40  41  42  43  44  45  46  47  48  49  50  51  52  53 1  2  3  4  5  6  7  8  9  10  11  12  13  14  15  16  17  18  19  20  21  22  23  24  25  26  27  28  29  30  31  32  33  34  35  36  37  38  39  40  41  42  43  44  45  46  47  48  49  50  51  52  53  54  55  56  57  58  59 1  2  3  4  5  6  7  8  9  10  11  12  13  14  15  16  17  18  19  20  21  22  23  24  25  26  27  28  29  30  31  32  33  34  35  36  37  38  39  40  41  42  43  44  45  46  47  48  49  50  51  52  53  54  55  56  57  58  59 1  2  3  4  5  6  7  8  9  10  11  12  13  14  15  16  17  18  19  20  21  22  23  24  25  26  27  28  29  30  31  32  33  34  35  36  37  38  39  40 1  2  3  4  5  6  7  8  9  10  11  12  13  14  15  16  17  18  19  20  21  22  23  24  25  26  27  28  29  30  31  32  33  34  35  36  37  38  39  40  41  42  43  44  45  46  47  48  49  50  51  52  53  54  55  56  57  58  59 The importance of cardiovascular health in relation to pregnancy outcome is increasingly 5 acknowledged. Women who develop certain pregnancy complications, in particular 6 preeclampsia, are at higher risk for future cardiovascular disease. Independent of its outcome, 7 pregnancy requires a substantial adaptive response of the maternal cardiovascular system. In 8 the HAPPO study, we aim to examine longitudinal maternal hemodynamic adaptation to 9 pregnancy from the preconception period onwards. We hypothesize that women who will 10 develop adverse pregnancy outcomes have impaired cardiovascular health before conception, 11 leading to hemodynamic maladaptation to pregnancy and diminished uteroplacental vascular 12 development. 13 14 Methods and analysis 15 In this prospective cohort study embedded in the Rotterdam periconception cohort, 200 16 women with a history of placenta-related pregnancy complications (high-risk group) and 100 17 women with an uncomplicated obstetric history (low-risk group) will be included. At five 18 moments (preconception, first-, second-and third trimester, and post-delivery), women will 19 undergo an extensive examination of the macro-and microcirculatory system and 20 uteroplacental vascular development. The main outcome measures are differences in 21 maternal hemodynamic adaptation to pregnancy between women with and without placenta- 22 related pregnancy complications. In a multivariate linear mixed model, the relationship 23 between maternal hemodynamic adaptive parameters, (utero)placental vascularization 24 indices and clinical outcomes (occurrence of pregnancy complications, embryonic and foetal 25 growth trajectories, miscarriage rate, gestational age at delivery, birth weight) will be studied. 26 Subgroup analysis will be performed to study baseline and trajectory differences between 27 high-and low-risk women, independent of subsequent pregnancy outcome. 28 29 Ethics and dissemination 30 This study protocol was approved by the Medical Ethics Committee of the Erasmus MC , 31 Rotterdam, the Netherlands (MEC 2018-150). Results will be disseminated to the medical 32 community by publications in peer-reviewed journals and presentations at scientific 1  2  3  4  5  6  7  8  9  10  11  12  13  14  15  16  17  18  19  20  21  22  23  24  25  26  27  28  29  30  31  32  33  34  35  36  37  38  39  40  41  42  43  44  45  46  47  48  49  50  51  52  53 congresses. Also, patient associations will be informed and the public will be informed by 2 dissemination through (social) media. 3 4 Registration details 5 Trial NL7394 1  2  3  4  5  6  7  8  9  10  11  12  13  14  15  16  17  18  19  20  21  22  23  24  25  26  27  28  29  30  31  32  33  34  35  36  37  38  39  40  41  42  43  44  45  46  47  48  49  50  51  52  53 Strengths and limitations of this study 4  An integrated approach consisting of parallel non-invasive techniques assessing 5 multiple hemodynamic parameters will compile extensive hemodynamic profiles of 6 participants. 7  Hemodynamic adaptation to pregnancy will be measured prospectively from the 8 preconception period onwards to three months post-delivery, thereby covering an 9 important window in the reproductive timespan. 10  Simultaneous assessment of maternal hemodynamic adaptation to pregnancy and 11 uteroplacental vascular development will provide new insights into the interaction 12 between both mechanisms and the pathophysiology of pregnancy complications. 13  Since only multiparous women will be included, conclusions about whether maternal 14 hemodynamic maladaptation is a cause or consequence of previous pregnancy 15 outcome cannot be provided. 1  2  3  4  5  6  7  8  9  10  11  12  13  14  15  16  17  18  19  20  21  22  23  24  25  26  27  28  29  30  31  32  33  34  35  36  37  38  39  40  41  42  43  44  45  46  47  48  49  50  51  52  53 Placenta-related pregnancy complications (PPC), such as preeclampsia and/or foetal growth 4 restriction, occur in approximately 10-15% of all pregnancies. 1-3 PPC not only affect perinatal 5 morbidity and mortality but also significantly impact the long-term cardiovascular health of 6 women and their children with associated health care costs for society. [4] [5] [6] For example, 7 women with a history of preeclampsia have a two-to sevenfold increased risk to develop 8 ischemic heart disease in later life, depending on the gestational age and severity at onset of 9 preeclampsia. 4 Thus, early identification of women who are at risk for PPC is not only 10 important to enable subsequent personalized prevention and treatment strategies in order to 11 improve reproductive outcome, but also to improve lifelong cardiovascular health. To date, 12 most available screening tests for adverse pregnancy outcome use blood pressure and uterine 13 artery blood flow, which reflect the hemodynamic profile of the mother, and thereby the 14 likelihood of impaired placental development and subsequent adverse events. Nonetheless, 15 these markers are not directly related to cardiac or placental function, which may explain the 16 moderate predictive performances of most prognostic models. 7 Hemodynamic adaptation to pregnancy 19 Pregnancy requires a physiological adaptive response of the maternal cardiovascular system 20 with a substantial rise in plasma volume and cardiac output (CO). 9 Already in the first trimester 21 of pregnancy, a woman's systemic vascular resistance decreases with 35-40% and her stroke 22 volume increases with 8%. 9 This natural volume overload leads to a reversible, physiological 23 left ventricular dilatation and a possible change in left ventricular diastolic function. 10 In most 24 pregnancies, these changes occur without clinical problems. However, in women who develop 25 PPC, maternal hemodynamic adaptation can be different and diastolic dysfunction is more 26 often present. 11 12 27 Moreover, in women with complicated pregnancies, endothelial dysfunction and increased 28 vascular stiffness are also more common. 13 14 The endothelial lining of the vasculature in the 29 human body is of great importance in the regulation of vascular tone. Vascular stiffness 30 increases during normal aging by the replacement of elastin fibres with less elastic collagen. 31 Endothelial function tests and arterial vascular stiffness measurements have already proven 32 to be of importance in predicting cardiovascular disease. 15 1  2  3  4  5  6  7  8  9  10  11  12  13  14  15  16  17  18  19  20  21  22  23  24  25  26  27  28  29  30  31  32  33  34  35  36  37  38  39  40  41  42  43  44  45  46  47  48  49  50  51  52  53 Together, this all supports the hypothesis that in women who develop PPC an increased risk 2 for cardiovascular disease is unmasked by the stressed state of pregnancy. 16 17 However, 3 knowledge on maternal hemodynamic adaptation to pregnancy, as early as the time of 4 conception, is scarce and often only focuses on one or two parameters instead of the complex 5 interaction between macro-and microcirculatory parameters. Only a few studies starting prior 6 to pregnancy have shown hemodynamic changes in, for example, blood pressure, heart rate 7 and CO early in pregnancy. [18] [19] [20] [21] [22] An integrated approach using parallel techniques and multiple 8 hemodynamic parameters from the preconception period onwards throughout pregnancy is 9 needed to provide insight in individual (patho)physiological hemodynamic adaptation to 10 pregnancy. 11 12 Placental development and function 13 The adequate establishment of the maternal-foetal vascular interface early in gestation is 14 essential for a healthy pregnancy outcome. Among others, this requires adaptation of the 15 uterine spiral arteries into remodelled vessels to create a low-resistance uteroplacental 16 circulation. 23 24 Failure in the adaptation of the uterine vasculature causes hypoperfusion of 17 the placenta and is widely believed to underlie several pregnancy complications. 25 26 This is 18 substantiated by several changes in histopathology, including decidual vasculopathy, villous 19 hypoplasia and lesions consistent with loss of integrity of the vascular wall of the maternal 20 circulation in delivered placentas of women with PPC. [27] [28] [29] However, the aetiology of these 21 placental abnormalities and its relation with maternal cardiovascular health remains unclear. 22 
23
RESEARCH HYPOTHESIS AND AIM 24 We hypothesize that impaired maternal cardiovascular health leads to hemodynamic 25 maladaptation to pregnancy, diminished uteroplacental vascular development and 26 subsequent pregnancy complications (Figure 1) . The overall aim of the HAPPO study is to 27 examine associations between maternal hemodynamic adaptation to pregnancy and 28 (utero)placental vascular development in women with and without (a history of) pregnancy 29 complications. Therefore, we specified the following objectives: 30 1. To assess hemodynamic parameters before, during and after pregnancy to gain insight 31 in (patho)physiological maternal hemodynamic adaptation mechanisms; 1  2  3  4  5  6  7  8  9  10  11  12  13  14  15  16  17  18  19  20  21  22  23  24  25  26  27  28  29  30  31  32  33  34  35  36  37  38  39  40  41  42  43  44  45  46  47  48  49  50  51  52  53 7 4. To study differences in baseline hemodynamic parameters and hemodynamic 8 adaptation to pregnancy between women with and without a history of PPC. 9 10 STUDY DESIGN 11 The HAPPO study is a single-centre prospective cohort study, embedded in the ongoing 12 Rotterdam periconception cohort, performed at the department of Obstetrics and 13 Gynaecology of the Erasmus MC, University Medical Centre Rotterdam, the Netherlands. 30 14 15 STUDY POPULATION 16 We aim to include 200 women with a history of pregnancy complications (i.e. preeclampsia 17 and/or foetal growth restriction [FGR]). Preeclampsia is defined according to the American 18 College of Obstetricians and Gynecologists (ACOG) criteria and FGR is defined conform the 19 Delphi consensus definition described by Gordijn et al. 1 31 20 Also, 100 women after uncomplicated pregnancies and (term) deliveries will be included as a 21 low-risk control group. Women are eligible to participate in this study when they have a 22 minimum age of 18 years, the delivery date of their last pregnancy was more than one year 23 ago, they have a current wish to become pregnant and the previous pregnancy was either 24 complicated by PPC or the previous pregnancy was uncomplicated. Women who are unable 25 or unwilling to provide informed consent will be excluded from participation. Also, if a woman 26 is currently breastfeeding, she will be excluded from participation since this may influence her 27 vascular condition. The in-and exclusion criteria are shown in Table 1 . 28 29 1  2  3  4  5  6  7  8  9  10  11  12  13  14  15  16  17  18  19  20  21  22  23  24  25  26  27  28  29  30  31  32  33  34  35  36  37  38  39  40  41  42  43  44  45  46  47  48  49  50  51  52  53 4 An overview of all study procedures is provided in Figure 2 . The first study visit will be planned 5 when the participating woman has the wish to become pregnant, but before conception takes 6 place. When a pregnancy occurs within one year, a study visit will be planned in each trimester 7 as well as three months post-delivery, which will be the last study visit. All communication 8 with the participants is coordinated by one researcher (RCB) who also performs all study 9 procedures during the study visits. 10 11 Questionnaires 12 Participants of the study will receive a total of three questionnaires: 1) after the 13 preconceptional study visit, participants will receive an online questionnaire on demographic 14 characteristics, medical conditions and lifestyle; 2) preceding the study visit in the first 15 trimester of pregnancy, participants will receive an online questionnaire to address possible 16 changes in medical conditions and lifestyle; 3) after delivery, participants will receive an online 17 follow-up questionnaire on pregnancy and birth outcomes (i.e. gestational age at birth, mode 18 of delivery, birth weight, neonatal sex, pregnancy and/or delivery complications). During the 19 post-delivery visit, the participants will, among others, be asked about current breastfeeding 20 and smoking habits. 21 
STUDY PROCEDURES/MEASUREMENTS
22
Anthropometrics 23 At each visit, a woman's height, weight, hip and waist circumference will be measured using 24 standardized, validated methods to compose the classical cardiovascular risk factors body 25 mass index (BMI) and waist-to-hip ratio. 32 
26
▪ 1  2  3  4  5  6  7  8  9  10  11  12  13  14  15  16  17  18  19  20  21  22  23  24  25  26  27  28  29  30  31  32  33  34  35  36  37  38  39  40  41  42  43  44  45  46  47  48  49  50  51  52  53  54  55  56  57  58  59 Two blood samples (8.5mL serum tube and 10mL EDTA tube) will be obtained at the 3 preconception visit, the first-and third-trimester visit, and the post-delivery visit. All samples 4 will be centrifuged and divided into aliquots of serum, plasma, whole blood and buffy coat 5 and then stored in a -80°C freezer at the trial laboratory at our own facility for future 6 assessment of cardiovascular markers (e.g. CRP and lipids) and markers of placental function 7 (e.g. PlGF and sFlt-1). 8 9 Echocardiography 10 Transthoracic echocardiography has become the preferential method for safe, non-invasive 11 cardiac assessment in pregnant women. 33 34 At all study visits, echocardiography will be Association of Cardiovascular imaging. 35 CO will be derived from the left ventricle outflow 16 tract velocity time integral (LVOT VTI) and LVOT cross-sectional area (LVOT CSA). From this, 17 systemic vascular resistance will be calculated (i.e. mean blood pressure divided by CO). Left 18 ventricular diastolic function will be assessed by mitral inflow (E/A) and tissue Doppler (E/e') 19 examination. Global left ventricular systolic function will be assessed by using the Teichholz 20 method for ejection fraction calculation. 36 
22
Post occlusion reactive hyperaemia 23 One of the first manifestations of an impaired cardiovascular risk profile is endothelial 24 dysfunction of small vessels (microcirculation). Post occlusion reactive hyperaemia (PORH) will 25 be used in this study to assess the endothelial function of the peripheral microvasculature. 26 We use devices from Moor instruments (moorVMS-VASC 2.0, moorVMS-PRES and moorVMS-27 LDF; Axminster, United Kingdom) to measure microvascular blood flow reactivity following 28 arterial occlusion by using a non-invasive laser Doppler flowmetry (LDF) technique. In resting 29 position, after three minutes of arterial occlusion by a cuff surrounding the upper left arm, the 30 reperfusion of microvascular blood in the skin is measured by the LDF skin probe which is 31 attached to the lower arm. The peak response after the release of the occlusion and the time 32 to recover to baseline reflect endothelial regulated microvascular function. 37 38 1  2  3  4  5  6  7  8  9  10  11  12  13  14  15  16  17  18  19  20  21  22  23  24  25  26  27  28  29  30  31  32  33  34  35  36  37  38  39  40  41  42  43  44  45  46  47  48  49  50  51  52  53  54  55  56  57  58  59 Pulse wave analysis 3 A cuff-based oscillometric device (Mobil-O-Graph® PWA by I.E.M., Stolberg, Germany) will be 4 used to assess central and peripheral blood pressure, pulse wave velocity and augmentation 5 index (AIx). 39 40 Pulse wave velocity values are derived from an algorithm which integrates age, 6 central systolic blood pressure and data derived from pulse wave analysis into a mathematical 7 model. 41 Higher values of pulse wave velocity indicate higher arterial stiffness and thus a 8 worse vascular condition. The AIx provides additional information on the stiffness of the aorta 9 and is derived from the central pressure waveform. 10 11 Cardiopulmonary exercise test with bio-impedance cardiography 12 To assess the hemodynamic response during physical stress, CO will also be measured using 13 signal morphology impedance cardiography (SM-ICG) using PhysioFlow® PF07 Enduro 14 (Manatec biomedical, Poissy, France). The exercise during which the SM-ICG will be 15 performed, is a cardiopulmonary exercise test (CPET) on a cycle ergometer with a RAMP 16 protocol to 70% of the estimated maximum heart rate according to the Tanaka formula. 42 
17
Moderate exercise limited to 70% of the maximal heart rate is considered safe during 18 pregnancy. 43 19 20 Uteroplacental vascularization measurements 21 Studies using conventional two-dimensional (2D) Doppler ultrasound have shown that 22 increased vascular resistance of the uterine arteries is associated with an increased risk for 23 subsequent development of PPC. 7 44 Therefore, pulsed wave Doppler measurements of the 24 right and left uterine artery will be performed at all study visits to provide the pulsatility and 25 resistance indices. Moreover, to evaluate the morphology of the uterine and placental 26 vasculature and quantification of perfusion, a 3D power Doppler scan of the uterine 27 (preconception visit) and placental bed (first-trimester visit) vasculature will be performed, 28 also using the Affiniti 70G ultrasound machine. By assessing these 3D datasets in an innovative 29 virtual reality (VR) system (Barco I-Space or 3D desktop), depth perception and three 30 dimensional interaction enables more accurate and detailed quantification of the 31 utero(placental) vascular volumes. At the Erasmus MC there is extensive experience with this 1  2  3  4  5  6  7  8  9  10  11  12  13  14  15  16  17  18  19  20  21  22  23  24  25  26  27  28  29  30  31  32  33  34  35  36  37  38  39  40  41  42  43  44  45  46  47  48  49  50  51  52  53  54  55  56  57  58  59 With respect to the risks of performing ultrasound examinations in the first trimester using 3D 4 power Doppler, recommendations as set by the International Society of Ultrasound in 5 Obstetrics and Gynaecology (ISUOG) are followed for the purpose of this study (i.e. thermal Embryonic and foetal growth parameters 11 At the first trimester visit, additional parameters of embryonic growth will be measured, i.e. 12 crown-rump length and embryonic volume. The obtained 3D datasets will be visualized in the 13 Barco I-Space or desktop version and offline volume measurements will be performed. 14 At the second and third trimester visit, additional parameters of foetal growth (head 15 circumference, abdominal circumference, femur length) and pulsed wave Doppler 16 measurements of the umbilical artery and median cerebral artery will be performed by 17 transabdominal ultrasound. 18 19 Placental examinations 20 At delivery, histological samples of in vivo placental vasculature will be harvested. The 21 placenta will be collected according to standard procedures and four samples of 22 approximately 3cm*3cm are then fixated in 4% paraformaldehyde for storage. The fixated 23 placenta biopsies will be processed and studied as done in routine placental pathology 24 examination. 25 In a subgroup of women who undergo a caesarean section (estimated 30% of our study 26 population) at the Erasmus MC, four punch biopsies of the placental bed will be collected, 27 which consist of decidual and myometrial tissue and contain spiral arteries. 49 The samples are 28 directly rinsed with sterile NaCl to wash excessive blood and then fixated in 4% 29 paraformaldehyde for storage and examination. According to our previously published 30 protocol, several markers will be used to score the developmental state of the spiral arteries, 31 identifying typical acute atherosis lesions and evaluating involvement of the immune 32 system. 49 50 1  2  3  4  5  6  7  8  9  10  11  12  13  14  15  16  17  18  19  20  21  22  23  24  25  26  27  28  29  30  31  32  33  34  35  36  37  38  39  40  41  42  43  44  45  46  47  48  49  50  51  52  53  54  55  56  57  58  59 The primary outcome measure of the HAPPO study is the difference in maternal hemodynamic 3 adaptation to pregnancy, expressed as the trajectory of CO assessed by echocardiography 4 before, during and after pregnancy, between women who do and do not develop PPC. CO is 5 one of the most frequently described hemodynamic parameters in pregnancy, alongside with 6 blood pressure. By using transthoracic echocardiography, as a validated and safe method to 7 measure CO, we will obtain consecutive and reliable information on maternal hemodynamic 8 adaptation to pregnancy. 34 
9
The secondary outcome measures are differences in additional indices of maternal 10 hemodynamic adaptation to pregnancy and utero(placental) vascular development between 11 women who do and do not develop PPC. This includes differences in weight gain during 12 pregnancy, blood pressure, systemic vascular resistance, left ventricular diastolic function, 13 endothelial regulated microvascular function, pulse wave analysis, hemodynamic response to 14 exercise, placental vascular indices, foetal growth parameters (including Doppler 15 measurements) and placenta/placental bed pathology examinations. 16 18 Since we aim to investigate multiple hemodynamic parameters and literature on this subject 19 is scarce, sample sizes are difficult to calculate. There are a few studies that describe the 20 longitudinal trajectory of CO from preconception until after delivery in uncomplicated 21 pregnancies and a couple of cross-sectional studies that investigated CO in either the first of 22 third trimester of pregnancy. 18-20 51 52 Based on these studies, we expect a difference of 23 approximately 0.5 standard deviation (SD) at each time point and an intraclass correlation 24 coefficient of at least 0.3 between time points in our study. With alpha set at 0.05 and a power 25 of 0.8, simulation for linear mixed model analysis based on these estimates showed that 38 26 cases (PPC in the anticipated pregnancy) are needed to establish such differences. 53 
17
SAMPLE SIZE CALCULATION
27
Based on literature, we expect a 25% recurrence rate of PPC in the high-risk group and a 2% 28 incidence of PPC in the low-risk group. [54] [55] [56] Thus, PPC cases will primarily occur in the high-risk 29 group. For an expected number of 38 cases we would need to follow-up 38/0.25=152 30 pregnancies in the high-risk group. 1  2  3  4  5  6  7  8  9  10  11  12  13  14  15  16  17  18  19  20  21  22  23  24  25  26  27  28  29  30  31  32  33  34  35  36  37  38  39  40  41  42  43  44  45  46  47  48  49  50  51  52  53 low risk for PPC and to increase the number of controls, we will also include 100 low-risk 7 women with an uncomplicated previous pregnancy. With this sample size we expect, based 8 on previous research, to be able to detect differences of approximately 5-10% in other 9 hemodynamic parameters and utero(placental) vasculature development (secondary 10 outcomes). 11 using t-tests. 17 Multivariate linear mixed models will be used to analyse the trajectories of maternal 18 hemodynamic parameters over time. We will test whether there is a difference between 19 women who do and do not develop PPC by comparing each trajectory using a likelihood ratio 20 test. 21 Subgroup analyses will be performed to study (baseline and trajectory) differences between 22 high-and low-risk women, independent of subsequent pregnancy outcome. Bonferroni 23 corrections will be applied to control for multiplicity of secondary outcome parameters. 24 In case of significant differences in patient characteristics between groups, regression analyses 25 will be adjusted for these characteristics. 26 
DATA COLLECTION, HANDLING AND STORAGE 28 The study will be performed according to written informed consent procedures which ensures 29 personal data protection and confidentiality. Data will be de-identified (pseudo-anonymized) 30 in order to guarantee the privacy of the participants, the key to the code will be safeguarded 31 by the investigators and will remain on site with the local research team. 1  2  3  4  5  6  7  8  9  10  11  12  13  14  15  16  17  18  19  20  21  22  23  24  25  26  27  28  29  30  31  32  33  34  35  36  37  38  39  40  41  42  43  44  45  46  47  48  49  50  51  52  53 All research data will be retained and stored in the HAPPO-database at a secured server at the 2 research institution and it will remain there for at least 15 years after completion of the 3 project. All imaging data will be stored and handled in the same way and according to the 4 same rules and regulations as other patient-related imaging data at Erasmus MC. 5 Monitoring of data and safety will be performed once a year, according to local protocol for 6 research with negligible risk. 7 8 PATIENT AND PUBLIC INVOLVEMENT 9 Patient and public were not involved in the design of the study. However, at the earliest 10 moment of recruitment, two large patient associations for women who experienced PE and/or 11 HELLP syndrome (i.e. HELLP Stichting [www.hellp.nl] and the Preeclampsia Foundation 12 [www.preeclampsia.org]) were informed and are involved in promoting the HAPPO study. 13 14 ETHICS AND DISSEMINATION 15 The study will be conducted according to the principles of the Declaration of Helsinki (version 16 October 2013) and in accordance with relevant national guidelines, regulations and Acts (e.g. 17 the Medical Research Involving Human Subjects Act [WMO]). The study protocol was 18 approved by the Medical Ethics Committee of the Erasmus MC (MEC-2018-150). The study is 19 registered in the Dutch Trial Registry (NL7394). 20 The HAPPO study team invites colleagues who are interested in collaboration or data sharing 21 to contact the principal investigators at HAPPO.studie@erasmusmc.nl. 22 Results of the study will be disseminated to healthcare professionals and to scientific and 23 industrial peers through events, professional organizations and publications in peer-reviewed 24 (preferably open-access) journals as well as presentations at scientific congresses. Also, results 25 will be communicated to women who wish to become pregnant and women who experienced 26 pregnancy complications by informing patient associations and by dissemination via (social) 27 media. 28 
29
FUTURE IMPLICATIONS 30 The results of this study will provide more understanding of longitudinal maternal 31 hemodynamic adaptation to pregnancy in relation to utero(placental) vascular development 1  2  3  4  5  6  7  8  9  10  11  12  13  14  15  16  17  18  19  20  21  22  23  24  25  26  27  28  29  30  31  32  33  34  35  36  37  38  39  40  41  42  43  44  45  46  47  48  49  50  51  52  53  54  55  56  57  58  59 and its associations with subsequent pregnancy outcome. If we succeed to establish an 2 association between maternal hemodynamic adaptation to pregnancy and subsequent 3 pregnancy outcome, a larger cohort study in nulliparous women will be needed to investigate 4 causal relationships between hemodynamic adaptation to pregnancy and placenta-related 5 outcomes. Hereby, starting points for future possibilities to optimize cardiovascular and 6 placental health by interventions in clinical validation studies will arise. This will enable the 7 development of more accurate, personalized prevention and treatment strategies for women 8 with high-risk pregnancies, from the preconception period onwards. Thereby, we aim to 9 reduce subsequent maternal and perinatal morbidity and mortality in the future, eventually 10 leading to life-long reduced risks and costs of cardiovascular diseases. 11 
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